Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ODC1 neoantigen peptide-pulsed dendritic cell vaccine
- Development stage
- Preclinical
- Lead developer
- Duke University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The ODC1 neoantigen peptide-pulsed dendritic cell vaccine is an autologous cellular immunotherapy developed at Duke University for the treatment of glioblastoma. The vaccine is prepared by loading (pulsing) a patient's own dendritic cells with a neoantigen peptide derived from Ornithine Decarboxylase 1 (ODC1), a protein involved in polyamine biosynthesis that is frequently dysregulated in brain tumors. Once administered, typically via intradermal injection, these dendritic cells present the ODC1 antigen to the immune system, aiming to stimulate a targeted CD8+ T-cell response against tumor cells. Research has also explored the use of systemic CCL3 as an adjuvant to enhance the migration of the vaccinated dendritic cells to lymph nodes, thereby improving the overall anti-tumor efficacy.
- Other names
- ODC1 peptide-pulsed DC vaccineODC-1 peptide-pulsed DC vaccineODC 1 peptide-pulsed DC vaccineODC1-DC vaccineODC-1-DC vaccineODC 1-DC vaccineODC1 neoantigen DC vaccineODC-1 neoantigen DC vaccineODC 1 neoantigen DC vaccine
02
Targets
Major histocompatibility complex class I/II molecules presenting Ornithine decarboxylase 1-derived neoantigen peptideCD28 (Cluster of Differentiation 28)PD-1 (Programmed cell death protein 1)T cell receptor specific for Ornithine decarboxylase 1 (ODC1)-derived neoantigen peptide–MHC complexODC1 (Ornithine decarboxylase 1)
Beyond the preview
Go deeper on ODC1 neoantigen peptide-pulsed dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ODC1 neoantigen peptide-pulsed dendritic cell vaccine.